Why Drugs Get Delayed: Blame It On Safety Concerns, Researchers Say
This article was originally published in The Pink Sheet Daily
Executive Summary
However, FDA allows manufacturers more leeway in providing additional data or new analyses to better understand a safety issue than an efficacy concern, according to a Health Affairs study of novel drugs approved after multi-cycle reviews.
You may also be interested in...
Mandatory FDA Review Of Pivotal Trial Protocols Urged In JAMA
Dartmouth researchers say that although FDA recommendations can strengthen study designs and improve outcome measures, sponsors often don’t follow agency’s advice or don’t even seek input in Phase III design.
Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows
Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.